Science_TechEconomy
News 9 of 31

Semaglutide Patent Expiry: Multi-Billion Dollar Opportunity for India's Generics, But Quality Risks Loom

Target:UPSC GS-IIIMPSCTeachingSSC GAPrelims HighMains HighStatic GK Link
14 Jul 2026
~2 min
Source: The Hindu
Key Data:20% of world's generic medicines by volumeOver 40 Indian firmsMore than 10 crore diabetes patients₹1,31,700 crore API market size (2025)₹15,000 crore PLI outlayMarch 2026 patent expiry in India
Bodies:Novo NordiskDr. Reddy's LaboratoriesSun PharmaMankind PharmaZydusLupinAlkemIQVIAUSFDAEMAUK MHRAWHOGilead SciencesPfizerSanofiBristol Myers SquibbNovartis
Practice MCQs from today's news ▸
What This Article Covers

1.Novo Nordisk's Semaglutide patent expired in India in March 2026, creating a major opportunity for Indian generic firms to produce lower-cost versions of Ozempic and Wegovy for diabetes and obesity.

2.Over 40 Indian companies, including Sun Pharma, Dr. Reddy's, and Mankind Pharma, announced plans to launch generic semaglutide, targeting India's 10 crore+ diabetes patients and export markets like Brazil and Canada.

3.Dr. Reddy's suspended supplies of its generic semaglutide after detecting impurities in API, highlighting quality control challenges that could undermine India's export credibility and delay entry into the complex peptide therapeutics segment.

The Big Picture
Prelims · HighMains · High

Semaglutide's patent expiry in India opens a multi-billion dollar market for generic drug makers, with over 40 firms planning launches. However, a quality lapse at Dr. Reddy's threatens India's reputation as a reliable supplier of 20% of the world's generic medicines, exposing systemic chinks in manufacturing compliance.

Exam Lens

Quick Exam Facts From News

India's share of global generics20% by volume
Indian firms planning semaglutide launchOver 40
Diabetes patients in IndiaMore than 10 crore
API market size in India (2025)₹1,31,700 crore
PLI outlay for pharma₹15,000 crore
Patent expiry of semaglutide in IndiaMarch 2026

1-Minute Revision

  • ›India's share of global generics: 20% by volume
  • ›Indian firms planning semaglutide launch: Over 40
  • ›Target this Data: India supplies 20% of the world's generic medicines by volume; API market size ₹1,31,700 crore (2025); PLI outlay ₹15,000 crore.
  • ›Target this Nodal Body: The Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals) administers the PLI scheme for pharma (inferred, not explicitly mentioned but standard).
  • ›Target this Legal Point: Patent expiry of semaglutide in India occurred in March 2026; the Supreme Court's 2013 verdict on imatinib patent (Novartis) is a landmark case.

Mastered this topic? Test your knowledge with a full MCQ quiz.

Practice exam-style questions, track your score, and strengthen your recall.

Q1Static LinkageEasy

Which Indian pharmaceutical company suspended supplies of its generic semaglutide after detecting impurities in the active pharmaceutical ingredient (API)?

Q2Statement-basedHard

Consider the following statements:

1. India supplies about 20% of the world's generic medicines by volume.

2. India is the world's third largest pharmaceutical industry by value.

3. More than 40 Indian firms have announced plans to launch generic versions of semaglutide.

Which of the statements given above is/are correct?

Q3Data-centricMedium

According to the article, what was the estimated size of the Active Pharmaceutical Ingredient (API) market in India in 2025?

Q4Application/ImpactMedium

What is the primary challenge for Indian pharmaceutical companies in competing in the peptide therapeutics market, as highlighted in the article?

All 25 MCQs ▸
You finished this topic
Explore Related Topics
Related Current Affairs
Science & Tech Current Affairs

EU AI Act: High-Risk Compliance Deadline Extended to Dec 2027; India Seeks Opportunity

The EU AI Act, applicable from August 2, 2026, creates a risk-based regulatory framework for AI. While Indian firms face compliance challenges due to the Act's treatment of post-approval updates, India can build a services industry around the required paperwork and, via the India-EU Free Trade Agreement, become a recognised participant in the EU's conformity assessment ecosystem.

Intl. Relations Current Affairs

Graham Bill Targets India for Russian Oil, US Fed Hikes by 25 bps, Himalayan Monal Alters Calls: UPSC Daily

The Indian Express UPSC Key for September 19, 2026, covers a wide range of high-yield topics: the Graham Bill authorising 100% tariffs on Russian oil buyers (including India), US Federal Reserve rate hike of 25 basis points, a Himalayan monal study showing call frequency change due to human noise, India-China thaw at BRICS, Tata Sons boardroom battle, stubble burning red entry rules, new CBFC guidelines with drug warnings, and India's first mainstream PHEV. Each segment directly aligns with UPSC Prelims/Mains syllabus.

Intl. Relations Current Affairs

India-China Bilateral Trade Reaches $125 Bn (22.6% YoY) Post Xi-Modi Meet; BRICS AI Plan

The September 12, 2026 Xi-Modi meeting in New Delhi signals a diplomatic thaw in India-China relations. Bilateral trade surged to $125 billion (Jan-Aug 2026) with Indian exports up 41%. China also proposed a BRICS AI open-source initiative, offering rich fodder for UPSC topics on IR, economy, and technology governance.

Science & Tech Current Affairs

World Bank Report: Only 4.5% Jobs in Low-Income Countries Exposed to AI vs 14.2% in Rich Nations

A World Bank report reveals that AI poses a smaller threat to jobs in developing economies like India (4.5% exposure) compared to rich nations (14.2%). However, sectors reliant on outsourcing (call centers, back-office) face job losses. The report advises focusing on small language models (SLMs) for agriculture, education, and healthcare to avoid over-dependence on the US or China.

Environment Current Affairs

India's RE Capacity Crosses 200 GW, Solar & Green Hydrogen Lead Clean Energy Transition

India's renewable energy capacity crossed 200 GW (45% of total installed capacity), driven by solar and wind. Key schemes like PM Surya Ghar, PM-KUSUM, National Green Hydrogen Mission, and International Solar Alliance highlight India's climate leadership. This is exam-relevant for prelims data and mains analysis on energy transition, government schemes, and India's climate commitments.

Science & Tech Current Affairs

SHANTI Act Draft Rules Released: DAE Meets EDF for EPR Reactors, Targets 100 GWe Nuclear Capacity by 2047

India is opening its civil nuclear sector to private players under the SHANTI Act. DAE recently released draft rules for private participation and foreign reactor tech. A key meeting with French state-owned EDF discussed deploying EPR reactors and localising supply chains to meet the ambitious 100 GWe nuclear capacity target by 2047.

Intl. Relations Current Affairs

India's UPI Diplomacy: Zero-Cost DPI Exports to 24 Nations Builds Strategic Influence & Global South Leadership

India is exporting its Digital Public Infrastructure (DPI) – including UPI and India Stack – to 24 countries, positioning itself as the Global South's reference model. Unlike Western private platforms or China's state-controlled exports, India offers these systems at no charge with full local ownership. This article examines whether this 'goodwill diplomacy' can translate into durable strategic influence, or whether influence ultimately requires something a partner fears to lose.

Science & Tech Current Affairs

ISRO Launches EOS-05: India's First Geo-Imaging Satellite in Geosynchronous Orbit; SC Invokes Article 142 to Quash CJP Protest Cases

A day of high exam relevance: ISRO successfully launched EOS-05, India’s first dedicated geo-imaging satellite in geosynchronous orbit, breaking a failure streak. The Supreme Court used its extraordinary power under Article 142 to close cases linked to CJP protests, raising important constitutional questions. Other key updates include OpenAI’s new autonomous AI model, Manipur’s NRC-first demand for Census deferral, mistrust in GDP data, and Tata Chemicals’ Kenya dispute.